These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 32533190)

  • 1. Characteristics of genomic alterations in Chinese cholangiocarcinoma patients.
    Jiang G; Zhang W; Wang T; Ding S; Shi X; Zhang S; Shi W; Liu A; Zheng S
    Jpn J Clin Oncol; 2020 Sep; 50(10):1117-1125. PubMed ID: 32533190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific genomic alterations and prognostic analysis of perihilar cholangiocarcinoma and distal cholangiocarcinoma.
    Zheng Y; Qin Y; Gong W; Li H; Li B; Wang Y; Chao B; Zhao S; Liu L; Yao S; Shi J; Shi X; Wang K; Xu S
    J Gastrointest Oncol; 2021 Dec; 12(6):2631-2642. PubMed ID: 35070393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive analysis of genomic alterations of Chinese hilar cholangiocarcinoma patients.
    Feng F; Wu X; Shi X; Gao Q; Wu Y; Yu Y; Cheng Q; Li B; Yi B; Liu C; Hao Q; Zhang L; Gao C; Jiang X
    Int J Clin Oncol; 2021 Apr; 26(4):717-727. PubMed ID: 33387086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention.
    Lowery MA; Ptashkin R; Jordan E; Berger MF; Zehir A; Capanu M; Kemeny NE; O'Reilly EM; El-Dika I; Jarnagin WR; Harding JJ; D'Angelica MI; Cercek A; Hechtman JF; Solit DB; Schultz N; Hyman DM; Klimstra DS; Saltz LB; Abou-Alfa GK
    Clin Cancer Res; 2018 Sep; 24(17):4154-4161. PubMed ID: 29848569
    [No Abstract]   [Full Text] [Related]  

  • 5. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.
    Churi CR; Shroff R; Wang Y; Rashid A; Kang HC; Weatherly J; Zuo M; Zinner R; Hong D; Meric-Bernstam F; Janku F; Crane CH; Mishra L; Vauthey JN; Wolff RA; Mills G; Javle M
    PLoS One; 2014; 9(12):e115383. PubMed ID: 25536104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole-Genome DNA Methylation Profiling of Intrahepatic Cholangiocarcinoma Reveals Prognostic Subtypes with Distinct Biological Drivers.
    Liao H; Chen X; Wang H; Lin Y; Chen L; Yuan K; Liao M; Jiang H; Peng J; Wu Z; Huang J; Li J; Zeng Y
    Cancer Res; 2024 Jun; 84(11):1747-1763. PubMed ID: 38471085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma.
    Zhang R; Li Q; Fu J; Jin Z; Su J; Zhang J; Chen C; Geng Z; Zhang D
    BMC Cancer; 2021 Feb; 21(1):112. PubMed ID: 33535978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrative genomic analyses of European intrahepatic cholangiocarcinoma: Novel ROS1 fusion gene and PBX1 as prognostic marker.
    Plum PS; Hess T; Bertrand D; Morgenstern I; Velazquez Camacho O; Jonas C; Alidousty C; Wagner B; Roessler S; Albrecht T; Becker J; Richartz V; Holz B; Hoppe S; Poh HM; Chia BKH; Chan CX; Pathiraja T; Teo AS; Marquardt JU; Khng A; Heise M; Fei Y; Thieme R; Klein S; Hong JH; Dima SO; Popescu I; Hoppe-Lotichius M; Buettner R; Lautem A; Otto G; Quaas A; Nagarajan N; Rozen S; Teh BT; Goeppert B; Drebber U; Lang H; Tan P; Gockel I; Schumacher J; Hillmer AM
    Clin Transl Med; 2024 Jun; 14(6):e1723. PubMed ID: 38877653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.
    Boerner T; Drill E; Pak LM; Nguyen B; Sigel CS; Doussot A; Shin P; Goldman DA; Gonen M; Allen PJ; Balachandran VP; Cercek A; Harding J; Solit DB; Schultz N; Kundra R; Walch H; D'Angelica MI; DeMatteo RP; Drebin J; Kemeny NE; Kingham TP; Simpson AL; Hechtman JF; Vakiani E; Lowery MA; Ijzermans JNM; Buettner S; Koerkamp BG; Doukas M; Chandwani R; Jarnagin WR
    Hepatology; 2021 Sep; 74(3):1429-1444. PubMed ID: 33765338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive genomic profile of cholangiocarcinomas in China.
    Tian W; Hu W; Shi X; Liu P; Ma X; Zhao W; Qu L; Zhang S; Shi W; Liu A; Cao J
    Oncol Lett; 2020 Apr; 19(4):3101-3110. PubMed ID: 32256810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations of candidate tumor suppressor genes at chromosome 3p in intrahepatic cholangiocarcinoma.
    You HL; Huang WT; Liu TT; Weng SW; Eng HL
    Exp Mol Pathol; 2017 Dec; 103(3):249-254. PubMed ID: 29122566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinically significant genomic alterations in the Chinese and Western patients with intrahepatic cholangiocarcinoma.
    Xu S; Guo Y; Zeng Y; Song Z; Zhu X; Fan N; Zhang Z; Ren G; Zang Y; Rao W
    BMC Cancer; 2021 Feb; 21(1):152. PubMed ID: 33579226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma.
    Kendre G; Murugesan K; Brummer T; Segatto O; Saborowski A; Vogel A
    J Hepatol; 2023 Mar; 78(3):614-626. PubMed ID: 36528236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular profiling and prognostic analysis in Chinese cholangiocarcinoma: an observational, retrospective single-center study.
    Zhang C; You X; Zhang Q; Wang D
    Invest New Drugs; 2024 Feb; 42(1):24-34. PubMed ID: 37975978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BAP1 acts as a tumor suppressor in intrahepatic cholangiocarcinoma by modulating the ERK1/2 and JNK/c-Jun pathways.
    Chen XX; Yin Y; Cheng JW; Huang A; Hu B; Zhang X; Sun YF; Wang J; Wang YP; Ji Y; Qiu SJ; Fan J; Zhou J; Yang XR
    Cell Death Dis; 2018 Oct; 9(10):1036. PubMed ID: 30305612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma.
    Joseph NM; Tsokos CG; Umetsu SE; Shain AH; Kelley RK; Onodera C; Bowman S; Talevich E; Ferrell LD; Kakar S; Krings G
    J Pathol; 2019 Jun; 248(2):164-178. PubMed ID: 30690729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
    Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
    Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BAP1 dependent expression of long non-coding RNA NEAT-1 contributes to sensitivity to gemcitabine in cholangiocarcinoma.
    Parasramka M; Yan IK; Wang X; Nguyen P; Matsuda A; Maji S; Foye C; Asmann Y; Patel T
    Mol Cancer; 2017 Jan; 16(1):22. PubMed ID: 28122578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intrahepatic cholangiocarcinoma development in a patient with a novel BAP1 germline mutation and low exposure to asbestos.
    Brandi G; Deserti M; Palloni A; Turchetti D; Zuntini R; Pedica F; Frega G; De Lorenzo S; Abbati F; Rizzo A; Di Marco M; Massari F; Tavolari S
    Cancer Genet; 2020 Oct; 248-249():57-62. PubMed ID: 33093002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma.
    Cristinziano G; Porru M; Lamberti D; Buglioni S; Rollo F; Amoreo CA; Manni I; Giannarelli D; Cristofoletti C; Russo G; Borad MJ; Grazi GL; Diodoro MG; Giordano S; Sacconi A; Forcato M; Anastasi S; Leonetti C; Segatto O
    J Hepatol; 2021 Aug; 75(2):351-362. PubMed ID: 33741397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.